Vahaticor
Santa Clara, US · Founded 2021 · 2 known investors
VahatiCor develops the A-FLUX Reducer System, a self-expanding nitinol mesh implant placed in the coronary sinus to improve microvascular perfusion in patients with symptomatic coronary microvascular dysfunction (CMD). The device targets patients who experience chest pain despite normal angiograms.
Founders & leadership
HR
Harry RowlandChief Executive Officer
KV
Kevin Van BladelChief Technology Officer
MN
Mark NiggliChief Commercial Officer
MB
Marwan Berrada-SounniNamed on SEC filing
Board
BR
DS
Daniel SheehanBoard director
JC
Jerrett CreedBoard director
BS
Bruce SamuelsBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$21.2M disclosed across 1 round · 2025
▶$21.2MraisedDec 2025 · 19 investors · Other Health CareRule 506(b)
▶$21.2MraisedDec 2025 · 19 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Brian R. SmithDirector
- Marwan Berrada-SounniExecutive Officer, Director
- Daniel SheehanDirector
- Jerrett CreedDirector
- Bruce SamuelsDirector
- Offering amount
- $32.4M
- Amount sold
- $21.2M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Vahaticor do?
- VahatiCor develops the A-FLUX Reducer System, a self-expanding nitinol mesh implant placed in the coronary sinus to improve microvascular perfusion in patients with symptomatic coronary microvascular dysfunction (CMD). The device targets patients who experience chest pain despite normal angiograms.
- Who are Vahaticor's investors?
- Vahaticor's investors include Intuitive Ventures, S3 Ventures.
- How much funding has Vahaticor raised?
- Vahaticor has disclosed $21.2M raised across 1 round.
- Where is Vahaticor headquartered?
- Vahaticor is headquartered in Santa Clara, US.